Literature DB >> 30472677

Medina embolization device for the treatment of intracranial aneurysms: 18 months' angiographic results.

Idriss Haffaf1, Frédéric Clarençon1,2, Eimad Shotar1,2, Claudia Rolla-Bigliani1, Saskia Vande Perre1, Bertrand Mathon2,3, Mehdi Drir4, Nader-Antoine Sourour1.   

Abstract

BACKGROUND AND
PURPOSE: The Medina embolization device (MED) is a new flow disruption device combining the design of a detachable coil with an intrasaccular flow disrupter. Safety and short-term angiographic effectiveness of this device have recently been reported. However, long-term angiographic results are lacking. We report herein the 18 months' angiographic outcome in patients treated for a wide-neck intracranial aneurysm with the MED.
MATERIALS AND METHODS: Nineteen patients (17 female, mean age 50 years) with 20 wide-neck intracranial aneurysms (six ruptured; 14 unruptured) were treated by the MED between January 2015 and June 2016. Procedure-related complications were systematically recorded; discharge and 6-9 months' follow-up modified Rankin Scale scores were assessed. Angiographic mid-term and long-term follow-up were performed with a mean delay of 6.4±1.5 months (n=16 aneurysms) and 17.7±4.2 months (n=15 aneurysms), respectively. Occlusion rates were evaluated after the procedure and at the mid-term and long-term follow-up using the Roy-Raymond scale.
RESULTS: Embolization with the MED was feasible in all except two cases (2/20, 10%). One per-procedural perforation was recorded (1/20, 5%) and one MED deployment failed because of the aneurysm's shape (1/20, 5%). Three cases of thromboembolic complications were observed (3/20, 15%). Only one thromboembolic complication was responsible for clinical sequelae. Grade A occlusion rate was 61% (11/18) after the procedure, 75% at 6 months' follow-up (12/16), and 80% (12/15) at long-term follow-up. Two cases (2/18, 11%) of recanalization at mid-term were documented angiographically. No recanalization occurred between the mid-term and long-term follow-up.
CONCLUSION: MED is a hybrid embolization device, combining properties of a conventional coil with those of an intrasaccular flow disrupter. Our series focusing on long-term angiographic follow-up shows a satisfactory long-term occlusion rate. Larger series with longer angiographic follow-up times are warranted to confirm these preliminary results. © Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  aneurysm; device; neck

Mesh:

Year:  2018        PMID: 30472677     DOI: 10.1136/neurintsurg-2018-014110

Source DB:  PubMed          Journal:  J Neurointerv Surg        ISSN: 1759-8478            Impact factor:   5.836


  5 in total

Review 1.  Microsurgical clipping versus newer endovascular techniques in treatment of unruptured anterior communicating artery-complex aneurysms: a meta-analysis and systematic review.

Authors:  F Diana; A Pesce; G Toccaceli; V Muralidharan; E Raz; M Miscusi; A Raco; P Missori; S Peschillo
Journal:  Neurosurg Rev       Date:  2021-10-07       Impact factor: 3.042

2.  pCONUS 2 and pCONUS 2-HPC for the treatment of wide-necked intracranial aneurysms: Periprocedural, 6-month, and early 2-year follow-up outcomes.

Authors:  J Yeomans; A Sastry
Journal:  Interv Neuroradiol       Date:  2021-04-22       Impact factor: 1.610

3.  High frequency optical coherence tomography assessment of homogenous neck coverage by intrasaccular devices predicts successful aneurysm occlusion.

Authors:  Robert M King; Miklos Marosfoi; Jildaz Caroff; Giovanni J Ughi; Dale M Groth; Matthew J Gounis; Ajit S Puri
Journal:  J Neurointerv Surg       Date:  2019-04-29       Impact factor: 5.836

Review 4.  Endovascular Treatment of Intracranial Aneurysms.

Authors:  Antonis Adamou; Maria Alexandrou; Christian Roth; Achilles Chatziioannou; Panagiotis Papanagiotou
Journal:  Life (Basel)       Date:  2021-04-10

5.  Risk Factors for Recurrence of Intracranial Aneurysm After Coil Embolization: A Meta-Analysis.

Authors:  Ji Jin; Geng Guo; Yeqing Ren; Biao Yang; Yongqiang Wu; Shule Wang; Yanqi Sun; Xiaogang Wang; Yuxiao Wang; Jianzhong Zheng
Journal:  Front Neurol       Date:  2022-07-22       Impact factor: 4.086

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.